Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adc Therapeutics Sa (NY: ADCT )

3.320 -0.010 (-0.30%)
Streaming Delayed Price Updated: 11:36 AM EDT, May 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adc Therapeutics Sa

< Previous 1 2 3 4 5 6 7 Next >
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
From ADC Therapeutics SA
Via Business Wire
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
Via Benzinga
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
From ADC Therapeutics SA
Via Business Wire
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: 
Via Benzinga
ADC Therapeutics: Q1 Earnings Insights
ADC Therapeutics (NYSE:ADCT) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: ADC Therapeutics Q4 Earnings
ADC Therapeutics (NYSE:ADCT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
From ADC Therapeutics
Via Business Wire
ADC Therapeutics to Present at the Jefferies Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here's What You Need To Know
RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
90 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Down 6%; Palantir Technologies Shares Slide
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Monday. 
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 450 Points; Hemisphere Media Group Shares Surge
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping around 450 points on Monday. 
Via Benzinga
40 Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces CEO Transition
From ADC Therapeutics SA
Via Business Wire
Earnings Outlook For ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC... 
Via Benzinga
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call
ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to... 
Via Benzinga
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
From ADC Therapeutics SA
Via Business Wire
Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'
Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating... 
Via Benzinga
Earnings Preview For ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
From ADC Therapeutics SA
Via Business Wire
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
From ADC Therapeutics SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.